HIV persistence remains a major challenge in developing effective treatments and achieving a potential cure. Even when antiretroviral therapy suppresses the virus, HIV can remain hidden in certain cells and tissues. Ongoing research explores viral reservoirs, immune responses, and innovative treatment approaches that may help eliminate persistent infection or support long-term remission without continuous medication.
HIV primarily targets CD4 T cells, which play an important role in coordinating the immune system. After entering these cells, the virus integrates its genetic material into the host cell's DNA. Some infected cells become long-lived and remain inactive, allowing HIV to persist without continuously producing new viral particles.
These infected cells are commonly described as latent viral reservoirs. Because dormant HIV does not actively replicate, antiretroviral medications cannot directly eliminate all reservoir cells. This explains why HIV can return when treatment is discontinued.
Researchers study several biological factors associated with HIV persistence, including:
Latent infection: HIV remains inactive inside certain immune cells, making it difficult for the immune system and medications to recognize infected cells.
Long-lived CD4 T cells: Some infected immune cells survive for extended periods and maintain viral genetic material.
Tissue reservoirs: HIV can persist in different body tissues, including lymphoid tissues and the central nervous system.
Immune system responses: Differences in immune activity can influence how effectively the body recognizes and controls infected cells.
Viral genetic material: Integrated HIV DNA can remain inside cells even when blood tests show viral suppression.
Researchers use laboratory studies, clinical investigations, and advanced molecular techniques to understand these processes. Measuring the size and activity of viral reservoirs is particularly important for evaluating experimental treatments.
Current HIV research focuses on developing strategies that target persistent viral reservoirs rather than only preventing active viral replication. Several experimental approaches are being investigated to understand whether HIV can be eliminated or controlled without lifelong medication.
One widely studied strategy is called shock and kill. It involves activating dormant HIV inside infected cells so that the immune system or other treatment mechanisms can recognize and eliminate them. However, activating latent HIV does not always result in the removal of infected cells, making this approach scientifically challenging.
Another approach is block and lock, which aims to maintain HIV in a permanently inactive state. Instead of activating dormant virus, researchers investigate methods that prevent it from becoming active again.
Other important research directions include:
Broadly neutralizing antibodies: These antibodies target different HIV strains and may help control viral activity while supporting immune responses.
Therapeutic vaccines: Researchers are studying vaccines designed to strengthen immune responses against HIV-infected cells.
Gene editing: Technologies such as CRISPR are being investigated for their potential to modify or remove HIV genetic material from infected cells.
Immune-based therapies: These approaches aim to improve the ability of immune cells to identify and eliminate infected cells.
Combination treatments: Researchers are examining whether combining different therapeutic strategies can produce stronger and more sustained effects.
Stem cell transplantation has also contributed to scientific understanding of HIV remission. A small number of individuals have experienced prolonged remission following complex stem cell transplants performed for serious blood cancers. However, these procedures carry significant risks and are not considered standard HIV treatment.
Clinical research continues to examine the effectiveness, safety, and long-term outcomes of these approaches. Antiretroviral therapy remains the established standard of care, and people living with HIV should continue prescribed treatment unless their healthcare professionals recommend otherwise.